RestructuringMay 12, 2026, 04:24 PM
AnaptysBio Completes Business Separation; Q1 Net Loss $(52.9)M
AI Summary
AnaptysBio, Inc. completed the separation of its business into two independent, publicly traded companies on April 20, 2026. The original company will focus on managing financial collaborations for Jemperli and imsidolimab royalties, while the spun-out entity, First Tracks Biotherapeutics, will develop autoimmune and inflammatory disease therapeutics. For the first quarter of 2026, AnaptysBio reported a net loss of $(52.9) million, an increase from $(39.3) million in the prior year, with collaboration revenue decreasing to $25.6 million.
Key Highlights
- Completed separation into two independent, publicly traded companies on April 20, 2026.
- Q1 2026 net loss increased to $(52.9) million from $(39.3) million in Q1 2025.
- Collaboration revenue decreased to $25.6 million in Q1 2026 from $27.8 million in Q1 2025.
- Basic and diluted net loss per share was $(1.84) in Q1 2026, up from $(1.28) in Q1 2025.
- Cash and cash equivalents increased to $248.5 million as of March 31, 2026.
- Total stockholders' equity decreased to $12.7 million as of March 31, 2026.
- Research and development expenses decreased to $34.0 million in Q1 2026.
- General and administrative expenses increased to $26.2 million in Q1 2026.
Price Impact
More from ANAB